Progesterone Therapy: Comprehensive Clinical Guide

Primary Indications for Progesterone

Progesterone must be added to estrogen therapy in all women with an intact uterus to prevent endometrial hyperplasia and cancer, reducing endometrial cancer risk by approximately 90%. 1, 2

Core Indications:

Endometrial protection in postmenopausal women receiving estrogen replacement therapy 1, 3
Hormone replacement therapy (HRT) in premature ovarian insufficiency (POI) after at least 2 years of estrogen-only therapy 1, 4
Pubertal induction in adolescents with chemotherapy- or radiation-induced POI (initiated after 2 years of estrogen or when breakthrough bleeding occurs) 1
Luteal phase support in assisted reproductive technology 5
Prevention of preterm birth in women with singleton gestations and prior spontaneous preterm birth or short cervix ≤20 mm at 18-24 weeks 1

Critical Contraindication:

Unopposed estrogen (without progesterone) increases endometrial cancer risk 10- to 30-fold after 5+ years of use, with relative risk escalating from 2.3 initially to 9.5-fold after 10 years. 1, 3, 2

Recommended Dosing Regimens

For Postmenopausal Women with Intact Uterus

First-line choice: Micronized progesterone 200 mg orally at bedtime for 12-14 days per 28-day cycle (sequential regimen), paired with transdermal 17β-estradiol 50-100 μg daily. 1, 3, 2, 4

Sequential Regimen Options:

Micronized progesterone: 200 mg orally daily for 12-14 days per month (preferred due to superior cardiovascular and breast safety profile) 1, 2, 6
Dydrogesterone: 10 mg orally daily for 12-14 days per month (second-line alternative) 1, 2
Medroxyprogesterone acetate (MPA): 10 mg orally daily for 12-14 days per month (third-line option with less favorable metabolic effects) 1, 2
Norethisterone: 5 mg orally daily for 12-14 days per month 1, 2

Continuous Combined Regimen Options (for women preferring amenorrhea):

Micronized progesterone: 100 mg orally daily without interruption 2, 4
Dydrogesterone: 5 mg orally daily continuously 2
MPA: 2.5 mg orally daily continuously 2
Norethisterone: 1 mg orally daily continuously 2

Alternative Route:

Vaginal micronized progesterone: 200 mg daily for 12-14 days per month (provides adequate endometrial protection with minimal systemic absorption) 2, 7

For Adolescents with Premature Ovarian Insufficiency

Begin cyclic progestogens only after at least 2 years of estrogen-only therapy or when breakthrough bleeding occurs. 1, 2

Micronized progesterone: 100-200 mg orally daily for 12-14 days per month 1, 2
Dydrogesterone: 5-10 mg orally daily for 12-14 days per month 1, 2

For Prevention of Preterm Birth

In singleton gestations with prior spontaneous preterm birth at 20-36 6/7 weeks: 17-hydroxyprogesterone caproate (17P) 250 mg intramuscularly weekly starting at 16-20 weeks until 36 weeks. 1

In singleton gestations with short cervix ≤20 mm at 18-24 weeks: Vaginal progesterone 90 mg gel daily or 200 mg suppository nightly from diagnosis until 37 weeks. 1

Critical Dosing Principles

The 12-14 Day Rule:

Never prescribe progesterone for fewer than 12 days per cycle in sequential regimens—this provides inadequate endometrial protection and fails to reduce endometrial cancer risk. 2

Estrogen Pairing Requirements:

Transdermal 17β-estradiol 50-100 μg daily is strongly preferred over oral formulations due to lower cardiovascular and thrombotic risk 1, 3, 2, 4
17β-estradiol is explicitly preferred over ethinylestradiol or conjugated equine estrogens 1, 2
Patches are changed twice weekly or weekly depending on brand 3, 4

Why Micronized Progesterone is Preferred:

Lower cardiovascular disease risk compared to synthetic progestins 2, 4, 5
Lower venous thromboembolism risk compared to MPA 3, 2, 4
Potentially lower breast cancer risk compared to synthetic progestins 3, 5
Fewer psychological side effects (less dysphoria, fatigue) compared to synthetic progestins 6
Better lipid profile effects compared to MPA 2, 6

Contraindications to Progesterone Therapy

Absolute Contraindications:

Active liver disease 1, 3
Current or history of breast cancer (for HRT indication) 1, 3, 4
Active or history of venous thromboembolism or pulmonary embolism 1, 3
Active or history of stroke 1, 3
Coronary heart disease or myocardial infarction 1, 3
Thrombophilic disorders 1, 3
Antiphospholipid syndrome or positive antiphospholipid antibodies 1, 3
Known or suspected estrogen-dependent neoplasia (when used with estrogen) 3

Relative Contraindications:

History of gallbladder disease (increased risk with oral HRT) 3
Smoking in women over age 35 (significantly amplifies cardiovascular and thrombotic risks) 3
Uncontrolled hypertension (transdermal route preferred if HRT necessary) 1

Special Population Considerations:

Gynecologic Cancer Survivors:

No contraindication for cervical, vaginal, or vulvar cancers (not hormone-dependent) 1
Favorable risk-benefit for most non-epithelial and epithelial ovarian cancers (high-grade, clear cell, mucinous) and early-stage endometrial cancer 1
Contraindicated in low-grade serous epithelial ovarian cancer, granulosa cell tumors, certain sarcomas (leiomyosarcoma, stromal sarcoma), and advanced endometrioid uterine adenocarcinoma 1

BRCA Mutation Carriers:

HRT is a treatment option for women with BRCA1/2 mutations without personal history of breast cancer after prophylactic bilateral salpingo-oophorectomy 1, 3
Generally contraindicated in breast cancer survivors 1

Duration of Therapy

For Women with Premature Ovarian Insufficiency or Surgical Menopause Before Age 45:

Continue HRT at least until the average age of natural menopause (51 years), then reassess. 1, 3, 4

For Women with Natural Menopause:

Use the lowest effective dose for the shortest duration consistent with treatment goals (symptom management, not chronic disease prevention). 1, 3, 2

Annual clinical review focusing on compliance, bleeding patterns, and symptom control 1, 2
Attempt dose reduction or discontinuation once symptoms are controlled 3, 2
Breast cancer risk does not appear until after 4-5 years of combined estrogen-progestin therapy 3
Other risks (stroke, VTE) emerge within the first 1-2 years 3

For Women Over 60 or More Than 10 Years Past Menopause:

Use the absolute lowest dose possible for the shortest time if HRT continuation is deemed essential; strongly consider discontinuation. 3

Monitoring and Follow-Up

Annual Assessment Should Include:

Compliance with therapy 1, 2
Bleeding pattern assessment (any abnormal bleeding requires evaluation) 3, 2
Symptom control (vasomotor symptoms, quality of life) 1, 2
Reassessment of risks versus benefits 3, 2
Development of new contraindications 3

No Routine Laboratory Monitoring Required:

No need for estradiol levels or FSH testing (management is symptom-based, not lab-based) 3
Laboratory tests may be prompted by specific symptoms or concerns 1

Common Clinical Pitfalls to Avoid

Never prescribe estrogen alone to women with an intact uterus—this dramatically increases endometrial cancer risk (RR 2.3-9.5) 1, 3, 2
Never use progesterone for fewer than 12 days per cycle in sequential regimens—inadequate endometrial protection 2
Do not initiate HRT solely for chronic disease prevention (osteoporosis, cardiovascular disease) in asymptomatic women—this is explicitly contraindicated (USPSTF Grade D recommendation) 3
Do not delay HRT initiation in women with surgical menopause before age 45 who lack contraindications—the window of opportunity for cardiovascular protection is time-sensitive 3
Do not assume all progestins have equal safety profiles—micronized progesterone has superior cardiovascular and breast safety compared to synthetic progestins 3, 2, 5, 6
Do not continue HRT beyond symptom management needs—breast cancer risk increases significantly with duration beyond 5 years 3
Do not use custom compounded bioidentical hormones or pellets—lack of data supporting safety and efficacy 3

Risk-Benefit Profile of Combined Estrogen-Progestin Therapy

For Every 10,000 Women Taking Combined Estrogen-Progestin for 1 Year:

Risks:

8 additional invasive breast cancers (RR 1.26-1.27) 1, 3
8 additional strokes (RR 1.39) 1, 3
8 additional pulmonary emboli (RR 2.03) 1, 3
7 additional coronary heart disease events 1, 3

Benefits:

75% reduction in vasomotor symptom frequency 1, 3
6 fewer colorectal cancers 1, 3
5 fewer hip fractures 1, 3
22-27% reduction in all clinical fractures (RR 0.73-0.78) 3

Estrogen-Alone Therapy (in women without uterus):

No increased breast cancer risk (may even be protective with RR 0.80) 1, 3
Similar stroke and VTE risks as combined therapy 3
No need for progesterone since no endometrium to protect 1, 3, 2

Special Clinical Scenarios

Women Requiring Contraception:

Consider 17β-estradiol-based combined oral contraceptives as first choice (with acetate nomegestrol or dienogest) rather than traditional HRT regimens. 1, 2

Women with Endometriosis Who Required Oophorectomy:

Combined estrogen-progestogen therapy is effective for vasomotor symptoms and may reduce risk of disease reactivation. 1

Women with Migraine:

Migraine should not be considered a contraindication to HRT use. 1, 4

Consider changing dose, route, or regimen if migraine worsens during HRT 1

Women with Hypertension:

Hypertension should not be considered a contraindication to HRT use in women with POI. 1

Transdermal estradiol is the preferred method of delivery in hypertensive women 1

Algorithm for Progesterone Prescribing

Step 1: Determine Uterine Status

Intact uterus → Progesterone REQUIRED with estrogen 1, 3, 2
Post-hysterectomy → Estrogen alone (no progesterone needed) 1, 3, 2

Step 2: Screen for Contraindications

Review absolute contraindications (active liver disease, history of VTE/stroke/MI, breast cancer, thrombophilic disorders, APS) 1, 3
Assess relative contraindications (smoking over age 35, gallbladder disease, uncontrolled hypertension) 3

Step 3: Select Progesterone Formulation

First choice: Micronized progesterone 200 mg orally at bedtime for 12-14 days per month 1, 2, 6
Second choice: Dydrogesterone 10 mg orally daily for 12-14 days per month 1, 2
Third choice: MPA 10 mg orally daily for 12-14 days per month 1, 2
Alternative route: Vaginal micronized progesterone 200 mg daily for 12-14 days per month 2, 7

Step 4: Pair with Appropriate Estrogen

Preferred: Transdermal 17β-estradiol 50-100 μg daily (patches changed twice weekly) 1, 3, 2, 4
Alternative: Oral 17β-estradiol 1-2 mg daily 2, 4

Step 5: Choose Sequential vs. Continuous Regimen

Sequential (12-14 days progesterone per month): Induces predictable withdrawal bleeding 2
Continuous (daily progesterone without interruption): Avoids bleeding, preferred by women desiring amenorrhea 2

Step 6: Establish Monitoring Plan

Annual clinical review (compliance, bleeding patterns, symptom control, risk reassessment) 1, 2
No routine laboratory monitoring unless specific symptoms arise 1, 3
Attempt dose reduction or discontinuation once symptoms controlled 3, 2

What are the indications, recommended dosing regimens, and contraindications for progesterone therapy in women of reproductive age and postmenopausal patients?

Help us tailor your experience